Artificial lung developer ALung raises $12m

Artificial lung-like device developer ALung Technologies said today it closed a $12 million round of financing to support the continued commercialization of its minimally invasive Hemolung Respiratory Assist System. Pittsburgh-based ALung’s Hemolung device is an extracorporeal carbon dioxide removal system that works by removing carbon dioxide and delivering oxygen directly to a patient’s blood via a small catheter inserted into the jugular or femoral vein. “This new financing reflects continued recognition by the investment community of the potential for our Hemolung technology to revolutionize the treatment of patients with acute respiratory failure. Very importantly, we will utilize this financing to complete the work required to obtain IDE approval for a US-based clinical trial under our recent EAP designation. We are very grateful to our investors for their continued confidence as we pursue this very exciting next step,” CEO Peter DeComo said in a prepared statement. ALung said the funds came from existing and new investors, and in addition to commercialization, funds will help support the company’s pursuit of FDA approval following the agency’s Expedited Access Pathway designation. The company raised $10.8 million of the funds last month, according to an SEC filing it posted in mid-January. The money already raised in the round comes from 63 unnamed investors, according to the SEC filing. The company said that the remaining ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Respiratory ALung Technologies Inc. Source Type: news

Related Links:

By ANISH KOKA   The year was 1965, the place was Boston Children’s and a surgery resident named Robert Bartlett took his turn at the bedside of a just born baby unable to breathe.  This particular baby couldn’t breathe because of a hole in the diaphragm that had allowed the intestines to travel up into the thoracic cage, and prevent normal development of the lungs.  In 1965, Robert Bartlett was engaged in the cutting edge treatment of the time – squeeze a bag that forced oxygenated air into tiny lungs and hope there was enough functioning lung tissue to participate in gas exchange to allow ...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: blogs
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians. A 58-year-old man is evaluated in follow-up for idiopathic pulmonary fibrosis (IPF), which was diagnosed 2 years ago. He has cough and shortness of breath and now requires supplemental oxygen at rest. Previous evaluations have not identified any cause for his symptoms other than progressive IPF. He has participated in pulmonary rehabilitation and continues in a maintenance program. He is a lifelong nonsmoker. His medical history is otherwise unremarkable, and he takes no medications. On physical examinat...
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Conditions Pulmonology Source Type: blogs
cs JA Abstract Pneumocystis, a unique atypical fungus with an elusive lifestyle, has had an important medical history. It came to prominence as an opportunistic pathogen that not only can cause life-threatening pneumonia in patients with HIV infection and other immunodeficiencies but also can colonize the lungs of healthy individuals from a very early age. The genus Pneumocystis includes a group of closely related but heterogeneous organisms that have a worldwide distribution, have been detected in multiple mammalian species, are highly host species specific, inhabit the lungs almost exclusively, and have never co...
Source: Clinical Microbiology Reviews - Category: Microbiology Authors: Tags: Clin Microbiol Rev Source Type: research
This review looks at the findings from recent clinical trials regarding the use of immunosuppression after lung transplantation.Seminars in Respiratory and Critical Care Medicine
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news
Publication date: 25 August 2018 Source:International Journal of Pharmaceutics, Volume 547, Issues 1–2 Author(s): The-Thien Tran, Celine Vidaillac, Hong Yu, Valerie F.L. Yong, Dan Roizman, Ravishankar Chandrasekaran, Albert Y.H. Lim, Teck Boon Low, Gan Liang Tan, John A. Abisheganaden, Mariko Siyue Koh, Jeanette Teo, Sanjay H. Chotirmall, Kunn Hadinoto Non-cystic fibrosis bronchiectasis (NCFB) characterized by permanent bronchial dilatation and recurrent infections has been clinically managed by long-term intermittent inhaled antibiotic therapy among other treatments. Herein we investigated dry powder inhaler (DPI) ...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
ConclusionsIn our experience, pirfenidone may be safely continued until lung transplantation. Only one patient in our series experienced impaired wound healing related to a surgical issue, even when pirfenidone was continued until lung transplantation. We found no evidence of impaired wound healing or airway complications after lung transplantation in patients who were treated with pirfenidone before lung transplantation.
Source: Multidisciplinary Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Abstract Extracorporeal membrane oxygenation (ECMO) has become a routine method in thoracic surgery. Recent developments in lung transplantation have led to its widespread acceptance. Firstly, ECMO is increasingly being used to bridge patients to transplantation. The best results in this setting have been described with "awake ECMO". Secondly, ECMO has replaced cardio-pulmonary bypass as the intraoperative standard device in most centres and is used for treatment and prevention of primary graft dysfunction. Refinements of the devices in use and the cannula design allow an individualised approach tailored...
Source: Zentralblatt fur Chirurgie - Category: Surgery Authors: Tags: Zentralbl Chir Source Type: research
Response: We thank the authors for their comments, which we addressed in the discussion of our article. We found no evidence of a Nocardia outbreak to explain the increase in nocardial infections, which occurred over a period of several years at multiple locations 1. Furthermore, since the lung is the most common site of nocardial infection in both sporadic cases as well as in reported outbreaks, the occurrence of only pulmonary cases in our report does not necessarily imply that there was a localized outbreak.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
In the original publication, Fig.  3 has been incorrectly published. The correct version of Fig. 3 is given in this Correction.
Source: Surgery Today - Category: Surgery Source Type: research
Conclusion: Our study proved that CBP could downregulate the p38 MAPK signaling pathway, suppress iNOS expression, reduced the serum levels of nitric oxide and TNF- α, thus ameliorate symptom of MOF.Kidney Blood Press Res 2018;43:938 –950
Source: Kidney and Blood Pressure Research - Category: Urology & Nephrology Source Type: research
More News: Clinical Trials | Lung Transplant | Medical Devices | Respiratory Medicine